[go: up one dir, main page]

AR065804A1 - Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento - Google Patents

Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento

Info

Publication number
AR065804A1
AR065804A1 ARP080101156A ARP080101156A AR065804A1 AR 065804 A1 AR065804 A1 AR 065804A1 AR P080101156 A ARP080101156 A AR P080101156A AR P080101156 A ARP080101156 A AR P080101156A AR 065804 A1 AR065804 A1 AR 065804A1
Authority
AR
Argentina
Prior art keywords
alkyl
group
heteroaryl
substituted
cycloalkyl
Prior art date
Application number
ARP080101156A
Other languages
English (en)
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of AR065804A1 publication Critical patent/AR065804A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Compuestos de indol carboxamida de la formula (1) en la que: R1 es el grupo -YZ; Y es un enlace, alquileno C1-6, alquenileno C2-6, o alquinileno C2-6; Z es arilo opcionalmente sustituido o heteroarilo opcionalmente sustituido, donde dichos arilo y heteroarilo están opcionalmente sustituidos con uno a tres sustituyentes, cada uno de ellos seleccionado independientemente entre el grupo que consiste en: halo, -CN, alquilo C1-6 opcionalmente sustituido, haloalquilo C1-6 opcionalmente sustituido, heteroarilo opcionalmente sustituido con uno a tres grupos alquilo C1-6; -N(Rb)SO2Re, -N(Rb)C(O)Ra, -C(O)NRaRb, -C(O)NRfRg, -C(O)H, -SO2Ri, -NRaRb, -SO2NRaRb, -SO2NRfRg, -ORc, -SRb, -N(Rb)C(O)NRaRb, -N(Rb)C(O)NRfRg y -N(Rb)C(O)ORd, donde dichos alquilo C1-6 y haloalquilo C1-6 están opcionalmente sustituidos con uno a tres sustituyentes, cada uno de ellos seleccionado independientemente entre el grupo que consiste en: -CN, -NRaRb, -N(Rb)SO2Re-, -C(O)Ra, -C(O)NRaRb, -SO2Ri, -SO2NRaRb, cicloalquilo C3-6, -ORc, -SRb, fenilo y heterocicloalquilo opcionalmente sustituido con uno o dos grupos alquilo C1-6; R2 es un heterocicloalquilo de 4-10 miembros opcionalmente sustituido que contienes, S, S=O, o S(O)2 como átomo(s) miembro(s) y los átomos miembros restantes son carbono, estando dicho heterocicloalquilo de 4-10 miembros opcionalmente sustituido con uno a tres sustituyentes, cada uno de ellos seleccionado independientemente entre al grupo que consiste en OH, alquilo C1-6 y fenilo; o R2 es el grupo biciclo de formula (2); en la que A es un grupo de union seleccionado entre: -CH2-CH2- o -CH2-X-CH2 y conecta los átomos de carbono 1 o 2 con los átomos de carbono 3 o 4; X es O, NR5 o S(O)n; R5 es H, alquilo C1-6 o -SO2NRaRb; y cada n es independientemente 0, 1 o 2; cada uno de R3 y R4 es independientemente H o fluor; m es 0 o 1; cada Ra se selecciona independientemente entre el grupo consistente en: H, alquenilo C2-6, alquilo C1-6, alquilo C1-6 sustituido con uno a tres sustituyentes seleccionados independientemente entre el grupo que consiste en: halo, CN, C(O)NH2, N(CH3)2, SO2Ri, CO(O)Rb, -N(Rb)C(O)Rb, -ORc, -SRc, cicloalquilo C3-7, haloalquilo C1-6, heterocicloalquilo, fenilo y heteroarilo; fenilo y fenilo sustituido con uno a tres sustituyentes seleccionados independientemente entre el grupo que consiste en: halo, alquilo C1-6, haloalquilo C1-6, NH2, heteroarilo, -ORc, y -NRfRg; heteroarilo, heteroarilo sustituido con uno a tres sustituyentes seleccionados independientemente entre el grupo que consiste en: halo, alquilo C1-6, haloalquilo C1-6, NH2, heteroarilo, -ORc y -NRfRg, cicloalquilo C3-7, cicloalquilo C3-7 sustituido con uno a tres sustituyentes seleccionados entre el grupo que consiste en: halo, alquilo C1-6, haloalquilo C1-6, NH2, heteroarilo, -ORc y -NRfRg; heterocicloalquilo y heterocicloalquilo sustituido con uno a tres sustituyentes seleccionados independientemente entre el grupo que consiste en: halo, alquilo C1-6, haloalquilo C1-6, NH2, heteroarilo, -ORc y -NRfRg; cada Rb se selecciona independientemente entre el grupo consistente en: H, alquilo C1-6 y cicloalquilo C3-7; cada Rc se selecciona independientemente entre el grupo consistente en H, alquilo C1-6, alquilo C1-6 sustituido con uno a tres sustituyentes seleccionados independientemente entre el grupo que consiste en: OH, cicloalquilo C3-6, fenilo, heterocicloalquilo, y heteroarilo; haloalquilo C1-6, haloalquilo C1-6 sustituido con uno a tres sustituyentes seleccionados independientemente entre el grupo que consiste en: OH, cicloalquilo C3-6, fenilo. heterocicloalquilo, y heteroarilo; cicloalquilo C3-7, cicloalquilo C3-7 sustituido con uno a tres grupos alquilo C1-3, heterocicloalquilo, heterocicloalquilo sustituido con uno a tres grupos alquilo C1-3 arilo, arilo sustituido con uno a tres sustituyentes seleccionados independientemente entre el grupo que consiste en halo, alquilo C1-3, haloalquilo C1-3 y OH; heteroarilo y heteroarilo sustituido con uno a tres sustituyentes seleccionados independientemente entre el grupo que consiste en: halo, alquilo C1-3, haloalquilo C1-3 y OH; cada Rd es independientemente un alquilo C1-3 opcionalmente sustituido, estando dicho alquilo C1-3 opcionalmente sustituido con uno a tres sustituyentes seleccionados del grupo consistente en: cicloalquilo C3-6, fenilo opcionalmente sustituido y heteroarilo opcionalmente sustituido; y donde dicho fenilo y heteroarilo están opcionalmente sustituidos con uno a tres sustituyentes seleccionados entre el grupo que consiste en halo, alquilo C1-6, y cicloalquilo C3-6; cada Re se selecciona independientemente entre el grupo consistente en: alquilo C1-6, alquilo C1-6 sustituido con un sustituyente seleccionado entre el grupo que consiste en: fenilo, heteroarilo. heterocicloalquilo, y NRaRb; fenilo y fenilo sustituido con uno a tres sustituyentes seleccionados entre el grupo que consiste en: halo, CN, alquilo C1-6, haloalquilo C1-6, y ORh; heteroarilo, heteroarilo sustituido con uno a tres sustituyentes seleccionados entre el grupo que consiste en: halo, CN, alquilo C1-6, haloalquilo C1-6 y ORh; cicloalquilo C5-7, cicloalquilo C5-7 sustituido con uno a tres sustituyentes seleccionados entre el grupo que consiste en: halo, alquilo C1-6, y cicloalquilo C3-6; heterocicloalquilo y heterocicloalquilo sustituido con uno a tres sustituyentes seleccionados entre el grupo que consiste en: halo, alquilo C1-6, y cicloalquilo C3-6; cada uno de Rf y Rg se toma independientemente junto con el átomo de nitrogeno al que están unidos formando un anillo que tiene de 4 a 7 átomos miembros, donde dicho anillo contiene opcionalmente un heteroátomo adicional como un átomo miembro, estando dicho anillo saturado o insaturado pero sin que sea aromático, y estando dicho anillo opcionalmente sustituido con uno o dos sustituyentes alquilo C1-3; cada Rh se selecciona independientemente entre el grupo consistente en: H, alquilo C1-6, y haloalquilo C1-6; y cada Ri se seleccione independientemente entre el grupo que consiste en: cicloalquilo C3-7, OH y alquilo C1-3 opcionalmente sustituido con un OH; o una sal farmacéuticamente aceptable del mismo. Composicion farmacéutica que lo comprende y uso de dicho compuesto para preparar un medicamento util para tratar un trastorno mediado por la actividad inapropiada de IKK2, tal como artritis reumatoide, asma, rinitis o enfermedad pulmonar obstructiva cronica.
ARP080101156A 2007-03-23 2008-03-19 Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento AR065804A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US89655807P 2007-03-23 2007-03-23

Publications (1)

Publication Number Publication Date
AR065804A1 true AR065804A1 (es) 2009-07-01

Family

ID=39788926

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080101156A AR065804A1 (es) 2007-03-23 2008-03-19 Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento

Country Status (15)

Country Link
US (2) US8071584B2 (es)
EP (1) EP2139322A4 (es)
JP (1) JP2010522238A (es)
KR (1) KR20100015797A (es)
CN (1) CN101677547A (es)
AR (1) AR065804A1 (es)
AU (1) AU2008231105B2 (es)
BR (1) BRPI0809221A2 (es)
CA (1) CA2681821A1 (es)
CL (1) CL2008000829A1 (es)
EA (1) EA019030B1 (es)
MX (1) MX2009010270A (es)
PE (1) PE20081889A1 (es)
TW (1) TW200901970A (es)
WO (1) WO2008118724A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0400895D0 (en) * 2004-01-15 2004-02-18 Smithkline Beecham Corp Chemical compounds
AR050253A1 (es) * 2004-06-24 2006-10-11 Smithkline Beecham Corp Compuesto derivado de indazol carboxamida, composicion que lo comprende y su uso para la preparacion de un medicamento
US8063071B2 (en) * 2007-10-31 2011-11-22 GlaxoSmithKline, LLC Chemical compounds
JP2009516702A (ja) * 2005-11-18 2009-04-23 スミスクライン・ビーチャム・コーポレイション 化合物
CA2662080C (en) 2006-09-07 2012-07-17 F. Hoffmann-La Roche Ag A process for the manufacture of snac (salcaprozate sodium)
PE20081889A1 (es) 2007-03-23 2009-03-05 Smithkline Beecham Corp Indol carboxamidas como inhibidores de ikk2
EP2406249A1 (en) 2009-03-10 2012-01-18 Glaxo Group Limited Indole derivatives as ikk2 inhibitors
NZ603454A (en) 2010-05-07 2014-06-27 Glaxosmithkline Llc Indoles useful for treating cellular proliferation diseases such as cancer
WO2014210255A1 (en) * 2013-06-26 2014-12-31 Abbvie Inc. Primary carboxamides as btk inhibitors
DE112015001835T5 (de) 2014-04-17 2016-12-29 Sumitomo Chemical Company, Limited Verfahren zur Herstellung einer Nitroverbindung
US20160168089A1 (en) * 2014-12-12 2016-06-16 H. Lundbeck A/S Process for the manufacture of idalopirdine
MA41148A (fr) * 2014-12-12 2017-10-17 H Lundbeck As Procédé de fabrication d'idalopirdine
ES2926255T3 (es) * 2017-04-24 2022-10-24 Tesaro Inc Métodos de fabricación de niraparib
CN113024506B (zh) * 2021-03-18 2022-05-20 合肥工业大学 3-甲酰四氢噻喃化合物的制备方法
LT4387730T (lt) * 2022-09-08 2025-09-10 Redx Pharma Limited Uolienų inhibitoriaus kietosios formos

Family Cites Families (192)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CY1308A (en) 1979-12-06 1985-12-06 Glaxo Group Ltd Device for dispensing medicaments
US4353656A (en) 1980-10-14 1982-10-12 Xerox Corporation Moving coil, multiple energy print hammer system including a closed loop servo
CY1492A (en) 1981-07-08 1990-02-16 Draco Ab Powder inhalator
GB2169265B (en) 1982-10-08 1987-08-12 Glaxo Group Ltd Pack for medicament
US4778054A (en) 1982-10-08 1988-10-18 Glaxo Group Limited Pack for administering medicaments to patients
FI79651C (fi) 1982-10-08 1990-02-12 Glaxo Group Ltd Doseringsanordning foer medicin.
US4775761A (en) 1983-08-22 1988-10-04 Hoechst-Roussel Pharmaceuticals, Inc. 3-(piperidinyl)- and 3-(pyrrolidinyl)-1H-indazoles
DE3342632A1 (de) 1983-11-25 1985-06-05 Merck Patent Gmbh, 6100 Darmstadt Indolderivate
US5256673A (en) 1983-11-25 1993-10-26 Merck Patent Gesellschaft Mit Beschrankter Haftung Indole-3-yl-A-tetrahydropyridyl or piperidyl compounds
FR2585563B1 (fr) 1985-07-30 1993-11-12 Glaxo Group Ltd Dispositif pour administrer des medicaments a des patients
ES2059408T3 (es) 1987-02-10 1994-11-16 Abbott Lab Un proceso para la preparacion de un compuesto.
JPH0262875A (ja) 1988-05-23 1990-03-02 Wakunaga Pharmaceut Co Ltd 新規イソインドリン誘導体
PH30133A (en) 1989-09-07 1997-01-21 Abbott Lab Indole-, benzofuran-, and benzothiophene-containing lipoxygenase inhibiting compounds
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
US5254473A (en) 1990-03-16 1993-10-19 Jp Laboratories Solid state device for monitoring integral values of time and temperature of storage of perishables
GB9127376D0 (en) 1991-12-24 1992-02-19 Wellcome Found Amidino derivatives
JP2963288B2 (ja) 1992-01-14 1999-10-18 株式会社海洋バイオテクノロジー研究所 水中有害付着生物防除剤
CZ283425B6 (cs) 1992-04-02 1998-04-15 Smithkline Beecham Corporation Fenylové deriváty a farmaceutické prostředky s jejich obsahem
US5256873A (en) * 1992-09-03 1993-10-26 Eaton Corporation Multiple station through beam photoelectric sensor
US5330986A (en) 1992-11-24 1994-07-19 Hoechst-Roussel Pharmaceuticals Inc. Indole-7-carboxamide derivatives
FR2701026B1 (fr) 1993-02-02 1995-03-31 Adir Nouveaux dérivés de l'indole, de l'indazole et du benzisoxazole, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
AU6215594A (en) 1993-03-18 1994-10-11 Merck Sharp & Dohme Limited Indole derivatives as dopamine d4 antagonists
GB9305623D0 (en) 1993-03-18 1993-05-05 Merck Sharp & Dohme Therapeutic agents
WO1995001980A1 (en) * 1993-07-06 1995-01-19 Pfizer Inc. Bicyclic tetrahydro pyrazolopyridines
ES2189322T3 (es) 1994-06-15 2003-07-01 Wellcome Found Intermediarios utiles en la preparacion de inhibidores de encimas.
ZA951822B (en) 1994-12-23 1996-09-26 Glaxo Group Ltd Chemical compounds
DE19500689A1 (de) 1995-01-12 1996-07-18 Merck Patent Gmbh Indolpiperidin-Derivate
US5772085A (en) 1995-03-10 1998-06-30 Minnesota Mining And Manufacturing Free flow aerosol valves
BR9609353A (pt) 1995-06-07 1999-05-11 Sugen Inc Composição farmacêutica conveniente para administração em humanos processo para melhorar sintomas de uma desordem proliferativa celular e compostos
GB9610811D0 (en) 1996-05-23 1996-07-31 Pharmacia Spa Combinatorial solid phase synthesis of a library of indole derivatives
EP1077213A3 (en) 1996-06-14 2001-06-13 Eli Lilly And Company Inhibition of serotonin reuptake
US5846982A (en) 1996-06-14 1998-12-08 Eli Lilly And Company Inhibition of serotonin reuptake
WO1998006715A1 (en) 1996-08-09 1998-02-19 Smithkline Beecham Corporation Novel piperazine containing compounds
WO1998028292A1 (en) 1996-12-23 1998-07-02 Smithkline Beecham Corporation Novel piperidine containing compounds
GB9700226D0 (en) 1997-01-08 1997-02-26 Glaxo Group Ltd Inhalation device
MY117948A (en) 1997-01-13 2004-08-30 Glaxo Group Ltd Nitride oxide synthase inhibitors.
DE19723722A1 (de) 1997-05-30 1998-12-10 Schering Ag Nichtsteroidale Gestagene
CN1272842A (zh) 1997-08-06 2000-11-08 伊莱利利公司 作为速激肽受体拮抗剂的2－酰氨基丙胺类化合物
WO1999016766A1 (en) 1997-10-01 1999-04-08 Kyowa Hakko Kogyo Co., Ltd. Benzodioxole derivatives
AR013669A1 (es) 1997-10-07 2001-01-10 Smithkline Beecham Corp Compuestos y metodos
DE19756036A1 (de) 1997-12-17 1999-06-24 Merck Patent Gmbh Amid- und Harnstoffderivate
US6506766B1 (en) 1998-02-13 2003-01-14 Abbott Laboratories Glucocortiocoid-selective antinflammatory agents
DE19807993A1 (de) 1998-02-26 1999-09-02 Bayer Ag Verwendung von ß-Carbolinderivaten zur Bekämpfung von TNF-alpha-abhängigen Krankheiten
ES2220043T3 (es) 1998-02-27 2004-12-01 Kissei Pharmaceutical Co., Ltd. Derivados del indol y composiciones medicinales que los contienen.
PT1070056E (pt) 1998-03-14 2004-11-30 Altana Pharma Ag Inibidores de pde iii/iv a base de ftalazinona
US6589954B1 (en) 1998-05-22 2003-07-08 Scios, Inc. Compounds and methods to treat cardiac failure and other disorders
GB9811599D0 (en) 1998-05-30 1998-07-29 Glaxo Group Ltd Nitric oxide synthase inhibitors
ATE252572T1 (de) 1998-06-30 2003-11-15 Lilly Co Eli 5-ht1f agonisten
ME00370B (me) 1999-06-23 2011-05-10 Sanofi Aventis Deutschland SUPSTITUISANI BENZIMIDAZOLl
DE19928424A1 (de) 1999-06-23 2000-12-28 Aventis Pharma Gmbh Substituierte Benzimidazole
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
CA2380373A1 (en) 1999-08-13 2001-02-22 Seth Lederman Cyclobenzaprine for treating generalized anxiety disorder and compositions thereof
CO5180649A1 (es) 1999-09-01 2002-07-30 Abbott Lab Antagonistas de los receptores de los glucocorticoides para el tratamiento de la diabetes para el tratamiento de la diabetes
DE19951360A1 (de) 1999-10-26 2001-05-03 Aventis Pharma Gmbh Substituierte Indole
CA2390531A1 (en) 1999-11-08 2001-05-17 Wyeth ¬(indol-3-yl)-cycloalkyl|-3-substituted azetidines for the treatment of central nervous system disorders
US6245799B1 (en) 1999-11-08 2001-06-12 American Home Products Corp [(Indol-3-yl)-cycloalkyl]-3-substituted azetidines for the treatment of central nervous system disorders
OA11558A (en) 1999-12-08 2004-06-03 Advanced Medicine Inc Beta 2-adrenergic receptor agonists.
US6632666B2 (en) 2000-01-14 2003-10-14 Biolife Solutions, Inc. Normothermic, hypothermic and cryopreservation maintenance and storage of cells, tissues and organs in gel-based media
GB0003154D0 (en) 2000-02-12 2000-04-05 Astrazeneca Uk Ltd Novel compounds
EP1134221A1 (en) 2000-03-15 2001-09-19 Aventis Pharma Deutschland GmbH Substituted beta-carbolines as lkB kinase inhibitors
EP1268477B1 (en) 2000-03-15 2010-04-21 Sanofi-Aventis Deutschland GmbH Substituted beta-carbolines with ikb-kinase inhibiting activity
EP1209158A1 (en) 2000-11-18 2002-05-29 Aventis Pharma Deutschland GmbH Substituted beta-carbolines
AU2001255538B2 (en) 2000-04-24 2006-03-30 Bristol-Myers Squibb Company Heterocycles that are inhibitors of IMPDH enzyme
CN1814596A (zh) 2000-04-28 2006-08-09 阿卡蒂亚药品公司 毒蕈碱性激动剂
US6849655B2 (en) 2000-05-15 2005-02-01 Kissei Pharmaceutical Co., Ltd. Aqueous liquid formulations
US6414013B1 (en) 2000-06-19 2002-07-02 Pharmacia & Upjohn S.P.A. Thiophene compounds, process for preparing the same, and pharmaceutical compositions containing the same background of the invention
US6897231B2 (en) 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
US20050009876A1 (en) 2000-07-31 2005-01-13 Bhagwat Shripad S. Indazole compounds, compositions thereof and methods of treatment therewith
WO2002012265A1 (en) 2000-08-05 2002-02-14 Glaxo Group Limited 6.ALPHA., 9.ALPHA.-DIFLUORO-17.ALPHA.-`(2-FURANYLCARBOXYL) OXY!-11.BETA.-HYDROXY-16.ALPHA.-METHYL-3-OXO-ANDROST-1,4,-DIENE-17-CARBOTHIOIC ACID S-FLUOROMETHYL ESTER AS AN ANTI-INFLAMMATORY AGENT
DE60119124T2 (de) 2000-08-14 2006-11-30 Ortho-Mcneil Pharmaceutical, Inc. Substituierte pyrazole
AU2001279958A1 (en) 2000-08-17 2002-03-04 Celltech R And D Limited Bicyclic heteroaromatic derivatives for the treatment of immune and inflammatorydisorders
US6868504B1 (en) * 2000-08-31 2005-03-15 Micron Technology, Inc. Interleaved delay line for phase locked and delay locked loops
RU2003106192A (ru) 2000-09-06 2004-07-27 Орто-Макнейл Фармасьютикал, Инк. (Us) Способ лечения аллергий
JP4272338B2 (ja) 2000-09-22 2009-06-03 バイエル アクチェンゲゼルシャフト ピリジン誘導体
ES2527688T3 (es) 2000-09-29 2015-01-28 Glaxo Group Limited Derivados de morfolin-acetamida para el tratamiento de enfermedades inflamatorias
US6869956B2 (en) 2000-10-03 2005-03-22 Bristol-Myers Squibb Company Methods of treating inflammatory and immune diseases using inhibitors of IκB kinase (IKK)
AU2002211827B2 (en) 2000-10-03 2006-12-14 Bristol-Myers Squibb Company Amino-substituted tetracyclic compounds useful as anti-inflammatory agents and pharmaceutical compositions comprising same
AU2002211663A1 (en) 2000-10-12 2002-04-22 Smith Kline Beecham Corporation Nf-$g(k)b inhibitors
EP1328272A1 (en) 2000-10-12 2003-07-23 SmithKline Beecham Corporation Nf-kappa-b inhibitors
NZ525474A (en) 2000-10-26 2005-10-28 Tularik Inc Antiinflammation agents
JP2002193938A (ja) 2000-12-01 2002-07-10 Bayer Ag ４−アリールピリジン誘導体
US7122544B2 (en) 2000-12-06 2006-10-17 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto
GB0031179D0 (en) 2000-12-21 2001-01-31 Glaxo Group Ltd Nitric oxide synthase inhibitors
JP4307073B2 (ja) 2000-12-22 2009-08-05 ワイス ５−ヒドロキシトリプトアミン−６リガンドとしてのヘテロサイクルインダゾールおよびアザインダゾール化合物
US6484903B2 (en) 2001-01-09 2002-11-26 Riverwood International Corporation Carton with an improved dispensing feature in combination with a unique handle
WO2002060386A2 (en) 2001-02-01 2002-08-08 Bristol-Myers Squibb Company METHODS OF TREATING INFLAMMATORY AND IMMUNE DISEASES USING INHIBITORS OF IλB KINASE (IKK)
GB0103630D0 (en) 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
US7144908B2 (en) 2001-03-08 2006-12-05 Glaxo Group Limited Agonists of beta-adrenoceptors
DE10112151A1 (de) 2001-03-14 2002-09-19 Merck Patent Gmbh Substituierte Benzofuran-2-carbonsäureamide
ES2296923T3 (es) 2001-03-22 2008-05-01 Glaxo Group Limited Derivados formanilidas como agonistas del adrenorreceptor beta2.
US7291608B2 (en) 2001-04-30 2007-11-06 Glaxo Group Limited Anti-inflammatory 17.β.-carbothioate ester derivatives of androstane with a cyclic ester group in position 17.α
WO2002094265A1 (en) 2001-05-24 2002-11-28 Leo Pharma A/S A method of modulating nf-$g(k)b activity
KR20030097897A (ko) 2001-05-24 2003-12-31 레오 파마 에이/에스 신규한 피리딜 시아노구아니딘 화합물
US20030045515A1 (en) 2001-05-24 2003-03-06 Lise Binderup Combination medicament for treatment of neoplastic diseases
KR100600240B1 (ko) 2001-06-07 2006-07-13 에프. 호프만-라 로슈 아게 5-ｈｔ6 수용체 친화도를 갖는 신규한 인돌 유도체
JP2005500290A (ja) 2001-06-12 2005-01-06 グラクソ　グループ　リミテッド 抗炎症性の、１７β−カルボチオアートアンドロスタン誘導体である１７α複素環エステル
US6638679B2 (en) 2001-07-12 2003-10-28 Kodak Polychrome Graphics, Llc Photosensitive compositions having mixtures of alkoxy and non-alkoxy diazonium salt containing compounds
SE0102616D0 (sv) 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
SE0102617D0 (sv) 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
US20030127204A1 (en) 2001-09-06 2003-07-10 Varnell Daniel F. Amphoteric polymer resins that increase the rate of sizing development
ATE417606T1 (de) 2001-09-14 2009-01-15 Glaxo Group Ltd Phenethanolamin-derivate zur behandlung von erkrankungen der atemwege
US6849653B2 (en) 2001-09-19 2005-02-01 Pharmacia Corporation Substituted pyrazolyl benzenesulfamide compounds for the treatment of inflammation
ATE363473T1 (de) 2001-09-19 2007-06-15 Pharmacia Corp Substituierte pyrazoloverbindungen zur behandlung von entzündungen
AU2002341729A1 (en) 2001-09-19 2003-04-01 Pharmacia Corporation Substituted pyrazolyl compounds for the treatment of inflammation
US20030109550A1 (en) 2001-09-19 2003-06-12 Michael Clare Substituted indazole compounds for the treatment of inflammation
MXPA04004064A (es) 2001-10-30 2004-09-06 Pharmacia Corp Derivados heteroaromaticos de carboxamida para el tratramiento de la inflamacion.
WO2003042160A1 (en) 2001-11-13 2003-05-22 Theravance, Inc. Aryl aniline beta-2 adrenergic receptor agonists
CA2472746A1 (en) 2002-01-14 2003-07-24 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical formulations containing them and uses thereof
US6831093B2 (en) 2002-01-22 2004-12-14 The Regents Of The University Of California Non-steroidal ligands for the glucocorticoid receptor, compositions and uses thereof
US6646785B2 (en) 2002-01-31 2003-11-11 Corning Incorporated Fiber ring amplifiers and lasers
JP2005523276A (ja) 2002-02-14 2005-08-04 グラクソ　グループ　リミテッド Ｎ−［（１−ｎ−ブチル−４−ピペリジニル）メチル］−３，４−ジヒドロ−２ｈ−［１，３］オキサジノ［３，２−ａ］インドール−１０−カルボキシアミド（ｓｂ２０７２６６）またはその塩および乾燥造粒操作を含む方法
GB0204719D0 (en) 2002-02-28 2002-04-17 Glaxo Group Ltd Medicinal compounds
CA2477764A1 (en) 2002-03-26 2003-10-09 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
PL373043A1 (en) 2002-03-26 2005-08-08 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
DE10215316C1 (de) 2002-04-02 2003-12-18 Schering Ag Chinolin- und Isochinolin-Derivate, ein pharmazeutisches Mittel und ihre Verwendung als Entzündungshemmer
DE60315615T2 (de) 2002-04-03 2008-10-02 Bristol-Myers Squibb Co. Tricyclische verbindungen basierend auf thiophen und arzneimittel, die diese umfassen
EP1495016A2 (en) 2002-04-09 2005-01-12 Astex Technology Limited Heterocyclic compounds and their use as modulators of p38 map kinase
CA2481320A1 (en) 2002-04-11 2003-10-23 Merck & Co., Inc. 1h-benzo[f]indazol-5-yl derivatives as selective glucocorticoid receptor modulators
AR039280A1 (es) 2002-04-11 2005-02-16 Smithkline Beecham Corp Compuesto de aminotiofeno y su uso para preparar una composicion farmaceutica
JP2005523920A (ja) 2002-04-25 2005-08-11 グラクソ　グループ　リミテッド フェネタノールアミン誘導体
CA2485298C (en) 2002-05-09 2008-03-11 Pharmacia Corporation Substituted pyrazolyl compounds for the treatment of inflammation
US7186864B2 (en) 2002-05-29 2007-03-06 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
NZ536197A (en) 2002-05-30 2006-08-31 Neurosearch As 3-substituted quinuclidines and their use
DE60325051D1 (de) 2002-06-06 2009-01-15 Boehringer Ingelheim Pharma SUBSTITUIERTE 3-AMINO-THIENO(2,3-b)PYRIDINE-2-AMIDE UND HERSTELLUNGSVERFAHREN SOWIE DEREN VERWENDUNG
JP2005531608A (ja) 2002-06-06 2005-10-20 スミスクライン・ビーチャム・コーポレイション ＮＦ−κＢ阻害剤
US7074806B2 (en) 2002-06-06 2006-07-11 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
MXPA05000345A (es) 2002-07-08 2005-03-31 Pfizer Prod Inc Moduladores del receptor de glucocorticoides.
JP2006508042A (ja) 2002-07-18 2006-03-09 ブリストル−マイヤーズ　スクイブ　カンパニー グルココルチコイド受容体の修飾物質および方法
GB0217225D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicinal compounds
DE10237722A1 (de) 2002-08-17 2004-08-19 Aventis Pharma Deutschland Gmbh Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase
DE60322713D1 (de) 2002-08-21 2008-09-18 Boehringer Ingelheim Pharma Substituierte dihydrochinoline als glucocorticoid-mmimetika,verfahren zu deren herstellung, pharmazeutische zubereitungen und deren verwendung
EA011095B1 (ru) 2002-08-29 2008-12-30 Бёрингер Ингельхайм Фармасьютиклз, Инк. Производные 3-(сульфонамидоэтил)индола, предназначенные для использования в качестве миметиков глюкокортикоидов при лечении воспалительных, аллергических и пролиферативных заболеваний
GB0220730D0 (en) 2002-09-06 2002-10-16 Glaxo Group Ltd Medicinal compounds
US6911445B2 (en) 2002-09-12 2005-06-28 Wyeth Antidepressant cycloalkylamine derivatives of heterocycle-fused benzodioxans
US6919334B2 (en) 2002-09-12 2005-07-19 Wyeth Antidepressant azaheterocyclymethyl derivatives of 4,5-dihydroimidazo[1,4,5-de][1,4]benzoxazine
US7135479B2 (en) 2002-09-12 2006-11-14 Wyeth Antidepressant azaheterocyclylmethyl derivatives of heterocycle-fused benzodioxans
NZ538515A (en) 2002-09-16 2007-04-27 Glaxo Group Ltd Pyrazolo[3,4-b]pyridine compounds, and their use as phosphodiesterase inhibitors
GB0230045D0 (en) 2002-12-23 2003-01-29 Glaxo Group Ltd Compounds
EP1542996A4 (en) 2002-09-20 2009-11-18 Merck & Co Inc OCTAHYDRO-2H-NAPHTOc1,2-F INDOL-4-CARBONSUUREAMIDE DERIVATIVES AS SELECTIVE MODULATORS OF THE GLUCOCORTICOID RECEPTOR
GB0224084D0 (en) 2002-10-16 2002-11-27 Glaxo Group Ltd Novel compounds
ES2291733T3 (es) 2002-10-22 2008-03-01 Glaxo Group Limited Compuestos de ariletanolamina medicinales.
DK1556342T3 (da) 2002-10-28 2008-07-21 Glaxo Group Ltd Phenethanolaminderivat til behandling af respiratoriske sygdomme
GB0225030D0 (en) 2002-10-28 2002-12-04 Glaxo Group Ltd Medicinal compounds
GB0225540D0 (en) 2002-11-01 2002-12-11 Glaxo Group Ltd Medicinal compounds
GB0225535D0 (en) 2002-11-01 2002-12-11 Glaxo Group Ltd Medicinal compounds
WO2004050634A1 (en) 2002-12-02 2004-06-17 F. Hoffmann-La Roche Ag Indazole derivatives as crf antagonists
EP1569924A4 (en) 2002-12-06 2007-02-21 Smithkline Beecham Corp NF-KB FACTOR INHIBITORS
DE10259244A1 (de) 2002-12-17 2004-07-01 Merck Patent Gmbh N-(Indolethyl-)cycloamin-Verbindungen
US7329668B2 (en) 2003-02-25 2008-02-12 Bristol-Myers Squibb Company Pyrazolopurine-based tricyclic compounds and pharmaceutical compositions comprising same
GB0308466D0 (en) 2003-04-11 2003-05-21 Novartis Ag Organic compounds
US7176214B2 (en) 2003-05-21 2007-02-13 Bristol-Myers Squibb Company Imidazo-fused oxazolo[4,5-β]pyridine and imidazo-fused thiazolo[4,5-β]pyridine based tricyclic compounds and pharmaceutical compositions comprising same
TWI328009B (en) 2003-05-21 2010-08-01 Glaxo Group Ltd Quinoline derivatives as phosphodiesterase inhibitors
GB0316290D0 (en) 2003-07-11 2003-08-13 Glaxo Group Ltd Novel compounds
EP1651629A1 (en) 2003-07-31 2006-05-03 Boehringer Ingelheim Pharmaceuticals Inc. Substituted benzothiophene compounds and uses thereof
US7291733B2 (en) 2003-10-10 2007-11-06 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted tricyclic heterocycles and their uses
DE602004005881T2 (de) 2003-10-14 2008-01-17 Pharmacia Corp. Substituierte pyrazinonverbindungen zur behandlung von entzündungen
MXPA06004244A (es) 2003-10-14 2006-06-28 Glaxo Group Ltd Antagonistas del receptor muscarinico de la acetilcolina.
AR046225A1 (es) 2003-11-04 2005-11-30 Glaxo Group Ltd Compuesto de 8-azoniabiciclo(3.2.1)octano, composicion farmaceutica para el tratamiento de enfermedades mediadas por receptores de acetilcolina muscarinicos que lo comprende y uso del compuesto para preparar dicha composicion
US20060004043A1 (en) 2003-11-19 2006-01-05 Bhagwat Shripad S Indazole compounds and methods of use thereof
WO2005058892A1 (en) 2003-12-19 2005-06-30 Glaxo Group Limited Pyrazolo [3,4-b] pyridine compounds, and their use as phosphodiesterase inhibitors
US7572914B2 (en) 2003-12-19 2009-08-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
GB0400895D0 (en) 2004-01-15 2004-02-18 Smithkline Beecham Corp Chemical compounds
DE102004012069A1 (de) 2004-03-12 2005-09-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue aryl-haltige 5-Acylindolinone, deren Herstellung und deren Verwendung als Arzneimittel
GB0405933D0 (en) 2004-03-16 2004-04-21 Glaxo Group Ltd Compounds
GB0405937D0 (en) 2004-03-16 2004-04-21 Glaxo Group Ltd Compounds
AU2005223351A1 (en) 2004-03-16 2005-09-29 Glaxo Group Limited Pyrazolo[3,4-b]pyridine compound, and its use as a PDE4 inhibitor
AR050902A1 (es) 2004-04-27 2006-12-06 Glaxo Group Ltd Compuesto de quinuclidina, composicion farmaceutica que lo comprende y su usopara preparar dicha composicion
AR050253A1 (es) 2004-06-24 2006-10-11 Smithkline Beecham Corp Compuesto derivado de indazol carboxamida, composicion que lo comprende y su uso para la preparacion de un medicamento
WO2006000401A1 (en) 2004-06-28 2006-01-05 Glaxo Group Limited Substituted oxazines as glucocorticoid receptor modulators
WO2006000398A1 (en) 2004-06-28 2006-01-05 Glaxo Group Limited 2,3-benzoxazin derivatives as non-steroidal glucocorticoid receptor modulators
GB0418045D0 (en) 2004-08-12 2004-09-15 Glaxo Group Ltd Compounds
PE20060748A1 (es) 2004-09-21 2006-10-01 Smithkline Beecham Corp Derivados de indolcarboxamida como inhibidores de quinasa ikk2
JP4660553B2 (ja) 2004-10-19 2011-03-30 エフ．ホフマン−ラ ロシュ アーゲー キノリン誘導体
EP1841780B1 (en) 2005-01-10 2011-07-27 Glaxo Group Limited Androstane 17-alpha-carbonate derivatives for use in the treatment of allergic and inflammatory conditions
US20090124588A1 (en) 2005-01-10 2009-05-14 Glaxo Group Limited Androstane 17-Alpha-Carbonate for Use in the Treatment of Inflammatory and Allergic Conditions
US20090275570A1 (en) 2005-04-06 2009-11-05 Astrazeneca Ab Substituted heterocycles and their use as chk1, pdk1 and pak inhibitors
KR20130136010A (ko) 2005-04-13 2013-12-11 네우렉슨 인코포레이티드 Ｎｏｓ 저해 활성을 갖는 치환된 인돌 화합물
AU2006257360B2 (en) 2005-06-14 2012-07-12 Construction Research & Technology Gmbh Providing freezing and thawing resistance to cementitious compositions
KR20080021077A (ko) * 2005-06-30 2008-03-06 스미스클라인 비참 코포레이션 화합물
US8063071B2 (en) 2007-10-31 2011-11-22 GlaxoSmithKline, LLC Chemical compounds
ES2372701T3 (es) 2005-07-22 2012-01-25 Shionogi & Co., Ltd. Derivado de indol que tiene actividad antagonista del receptor de pgd2.
EP1940296A2 (en) * 2005-10-25 2008-07-09 SmithKline Beecham Corporation Chemical compounds
EP1940394A4 (en) 2005-10-25 2009-07-08 Smithkline Beecham Corp CHEMICAL COMPOUNDS
JP2009516702A (ja) 2005-11-18 2009-04-23 スミスクライン・ビーチャム・コーポレイション 化合物
JP2009519968A (ja) 2005-12-16 2009-05-21 スミスクライン・ビーチャム・コーポレイション 化学物質
EP2001480A4 (en) 2006-03-31 2011-06-15 Abbott Lab Indazole CONNECTIONS
US20080146606A1 (en) 2006-09-22 2008-06-19 Paul Bamborough Novel compounds
PE20081889A1 (es) 2007-03-23 2009-03-05 Smithkline Beecham Corp Indol carboxamidas como inhibidores de ikk2
GB0710528D0 (en) 2007-06-01 2007-07-11 Glaxo Group Ltd Novel compounds
GB0804592D0 (en) 2008-03-12 2008-04-16 Glaxo Group Ltd Novel compounds
EP2406249A1 (en) 2009-03-10 2012-01-18 Glaxo Group Limited Indole derivatives as ikk2 inhibitors
US20120058984A1 (en) 2009-03-17 2012-03-08 Catherine Mary Alder Pyrimidine derivatives used as itk inhibitors

Also Published As

Publication number Publication date
CL2008000829A1 (es) 2008-09-26
AU2008231105B2 (en) 2011-07-21
WO2008118724A1 (en) 2008-10-02
TW200901970A (en) 2009-01-16
US8372875B2 (en) 2013-02-12
PE20081889A1 (es) 2009-03-05
US20120040958A1 (en) 2012-02-16
EP2139322A4 (en) 2011-04-06
EP2139322A1 (en) 2010-01-06
CN101677547A (zh) 2010-03-24
MX2009010270A (es) 2009-10-12
KR20100015797A (ko) 2010-02-12
JP2010522238A (ja) 2010-07-01
EA200970883A1 (ru) 2010-04-30
US8071584B2 (en) 2011-12-06
CA2681821A1 (en) 2008-10-02
BRPI0809221A2 (pt) 2019-09-24
US20100130468A1 (en) 2010-05-27
EA019030B1 (ru) 2013-12-30
AU2008231105A1 (en) 2008-10-02

Similar Documents

Publication Publication Date Title
AR065804A1 (es) Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento
AR061101A1 (es) Compuesto de fenil-triazolil- metoxi- arilo, su uso para la manufactura de un medicamento y composicion farmaceutica que lo comprende
AR050540A1 (es) Derivados de adamantilamida triciclica como inhibidores de deshidrogenasa 11- beta hidroxiesteroide
AR074089A1 (es) Antagonistas de cicloalcano (b) azaindol de los receptores de la postaglandina d2
AR068840A1 (es) Moduladores del gpr40 bifenilo sustituidos y composiciones farmaceuticas que los contienen
PE20141209A1 (es) Inhibidores de la replicacion de virus influenza
AR071857A1 (es) Derivados de indazol sustituidos con fenilo y benzodioxinilo, una composicion farmaceutica que los comprende y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por el receptor de glucocorticoides.
AR074676A1 (es) Derivados de isooxazol como antagonistas de receptores de acido lisofosfatidico, composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades mediadas por la actividad fisiologica de lpa.
AR065354A1 (es) Derivados de 2-aminopirimidina, un metodo para su preparacion, una composicion farmaceutica que lo comprende y su uso en el tratamiento de enfermedades mediadas por el receptor de histamina h4.
AR088175A1 (es) 3-pirimidin-4-il-oxazolidin-2-onas utiles para tratar cancer y composiciones farmaceuticas que las contienen
PE20080409A1 (es) Compuestos que modulan en el receptor cb2
AR086977A1 (es) Derivados heterociclicos nitrogenados utiles para el tratamiento del cancer y composiciones farmaceuticas que los contienen
AR091279A1 (es) Inhibidores macrociclicos de virus flaviviridae
CO6321265A2 (es) Compuestos de 2-amido-3-metil pirrolo pirimidinona fenilo -sustituidos como inhibidores bace-1 composiciones y su uso
AR087711A1 (es) Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y uso de los mismos para el tratamiento de trastornos neurodegenerativos
AR085149A1 (es) Moduladores del receptor de glucagon
AR082763A1 (es) Derivados de piperidinona como inhibidores mdm2 para el tratamiento de cancer
AR080974A1 (es) Derivados piridinicos y piperazinicos moduladores de la actividad de los canales del calcio activado por depositos intracelulares(soc), composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades inflamatorias y trastornos inmunes, entre otras.
AR100806A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
JP2016530315A5 (es)
AR087909A1 (es) Composiciones farmaceuticas
AR092288A1 (es) Ligandos del receptor ep1
AR084011A1 (es) Compuestos nitrogenados heterociclicos utiles para el tratamiento de infecciones por el virus sincitial respiratorio (rsv), proceso para prepararlos y composiciones farmaceuticas que los contienen
AR100810A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR087915A1 (es) N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la bace1

Legal Events

Date Code Title Description
FA Abandonment or withdrawal